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BMJ Open RANDOMISED CONTROLLED TRIAL OF RHINOTHERMY FOR TREATMENT OF THE COMMON COLD Manuscript ID bmjopen-2017-019350
The authors present the results of an open, randomized, controlled, single center study on rhinothermy (medical device, high flow nasal cannulae) vs. Vitamin C in patients with common cold. The main aims of the study were to determine the feasibility of the trial design, exploratory efficacy regardi ng common cold, a minimum clinically important difference (MCID) for a specific outcome parameter, and the tolerability of the device. The manuscript is well written and illustrative. The medical condition (common cold) is i mportant. The proposed intervention is a novel, interesting approach for treatment. The study designs s eem generally sound. The results are well presented. I agree with the authors' conclusions, and I would recommend the publication of the manuscript after revision. I would be willing to take questions from the authors regarding any of my concerns in ord er to facilitate the revision process. Comments 1) Page 1, line 5-7 It should be stated in the title of the article that this was a feasibility study. Page 2, line 10 and page 7, line 8 2) This study was not placebocontrolled. A placebo for this study would be a (preferably) identical looking device (HFNC) without active ingredients. Vitamin C (the control intervention in t his study) is not a placebo. Although the effectiveness of Vitamin C is probably rather weak, this was (technically) an activecontrolled study. Thus, please refrain from using the term placebo in the manuscript. 3) For the planning of a further trial, randomizing to either rhinothermy + Vitamin C vs. Vita min C alone could be an option. 4) Please be consistent with the description of the trial design on page 2, line 10 and page 7, line 8. 5) Page 2, line 33-39 Please state only results which are in line with the objectives of the study (page 2, line 6) . 6) Entire manuscript Since this was an exploratory (not a confirmatory) trial, there is no formal level of signific ance. All pvalues are to be interpreted exploratory. This should be stated in the statistical analysis section. While it is important to present pvalues, the term 'significant' should be avoided throughout the entire manuscript. 7) Page 5, line 55 and page 6, line 2-4 It is not entirely clear what is meant by 'sample of the population from which participants would be 2/3 recruited into an RCT' and 'sample of the population from which participants would be re cruited.' Please clarify these 'samples'. 8) Page 11, line 25-27 Please state which model(s) included an interaction term. 9) Page 11, line 31-33 Please state for which time points logistic regression was used. Was this a repeated me asures regression model? 10) Page 14, Table 1 The table is informative and contains useful results. However, please rearrange the table to the usual layout of showing the results in columns by treatment (i.e. Rhinothermy treatment, Vitam in C treatment, All participants) next to each other, while Mean (SD), Median (IQR) and Min t o Max one underneath the other for each characteristic. One of the main purposes of this table is to compare the treatment groups, and it is easier for the reader if the values to be compared are nex t to each other. Page 15, Table 2 and in the entire manuscript 11) Please be consistent with the terms 'day 1' and 'baseline'. I suppose they refer to the sa me time point. If yes, please do not use two different terms (the preferable term would be 'baselin e' since this clearly indicates a time point BEFORE intervention). 12) Please be consistent with the number of decimal places shown (day 4). 13) Did the authors analyze the eight domains of the Jackson Score separately? 14) Would these analyses reveal some additional important insights? 15) Page 16, Table 3 Please indicate in the table header which outcome is presented in table 3. Again, the pre ferable term for 'day 1' would be 'baseline'. 16) Page 16, section 'Estimation of Minimal Clinically Important Difference (MCID) / Substan tial Clinical Benefit (SCB)' Another way to obtain an estimate for the MCID would be to calculate the mean of the c hange in modified Jackson score from baseline to the first day of reported feeling 'a lot better'. 17) Page 17, line 10 Please indicate the number of participants with a modified Jackson score of zero at day 10 separately per treatment group. Page 18, Figure 2 18) Some minor tick marks would be helpful to better estimate the values of the outcome. 3/3 19) In addition, horizontal lines (at the major and minor tick marks) would be helpful to better grasp the changes in the outcome. 20) Even though the values at day 1 are 0 for both groups, I would suggest including the bas eline values into the graph to demonstrate the rather big difference in Jackson scores from day 1 (ba seline) to day 2. 21) Please state at the y-axis what is shown (mean with 95% CI or SD?).
22)
Instead of a note at line 28/29, I would prefer to have a legend inside the box of the grap h (but this is merely a personal preference; completely optional). 23) Page 18, Figure 3 Another personal preference (and completely optional) is to display 1-S(t) (instead of S(t)), e.g. to mirror the curves, starting at zero. I think it is more intuitively to show the proportion who do feel better. Page 19, line 20-24 24) Please present results of the test of interaction (at least a pvalue for the test of interaction). 25) Please present these results where the outcomes of the the model including the interacti on term is shown (Table 3? ). 26) Page 20, Table 6 Please be consistent with the number of decimal places shown. Page 24, line 8-18 27) The authors give advice on the sample size of a future trial randomizing into three treatm ent arms. It is unclear how the overall alpha level is preserved when multiple testing is present and h ow this affects the total sample size. The authors might want to restrict the advice to a twoarmed trial to avoid this problem. 28) In addition, please increase the sample size to 43 subjects per treatment arm to properly account for a 10% drop-out rate. 29) Further comments (do not need to be addressed in the manuscript) Page 10, line 18 For a feasibility study, an additional qualitative part is often useful. Especially when a no vel intervention is used, several aspects such as handling, manageability, difficulties, possib le improvements, etc. are difficult to be captured by questionnaire with prespecified questions and answers. This would be better assessed by semistructured interviews or focus groups. While this cannot be done for the present study, it might still a useful option for a subsequent trial ( e.g. as a substudy).
REVIEWER
Harri Hemilä Department of Public Health University of Helsinki Finland REVIEW RETURNED 08-Oct-2017
GENERAL COMMENTS
Reviewer comments 2017-10-7
MAJOR COMMENTS
1. THE GOAL AND PRIMARY OUTCOME ARE NOT SOUND "8.1. Hypothesis This is a feasibility study to assess the process, resources, management and scientific aspects of NHF therapy use in participants with a specific criteria that determines a common cold diagnosis. This will inform a future randomised controlled trial design to ensure methodological robustness." (Protocol) "9.3. Bias The feasibility study is designed to inform a future randomized controlled trial. Therefore bias is not relevant for the outcomes of this study." (Protocol)
"The primary outcome measure was the proportion of recruits who were randomised" (p. 10, line 34) I do not consider that this kind of goal and primary outcome are relevant for a scientific journal. Drug companies and device producers may carry out pragmatic studies for various purposes, but I dont think the stated goals are relevant for medical readers. All pilot studies need not be published.
ADMINISTERING VITAMIN C TO THE CONTROL GROUP DOES NOT MAKE SCIENTIFIC SENSE
In the protocol, the authors write:
"9.2. Controls. Vitamin C tablets 250mg once per day for 5 days will be used. This will act as the 'control' group and simulate 'real world' practice. A Cochrane review reported that there is no strong evidence to support the use of Vitamin C to improve symptoms in the common cold [15] ." "9.10.1 Interventions b) "Vitamin C tablets" (N=10 participants)
This will act as the 'control' group; a Cochrane review reported that there is no strong evidence to support the use of Vitamin C to improve symptoms in the common cold [15] . Subjects randomised to this group will receive a Vitamin C tablet (Healtheries Vit C containing 250mg vitamin C)."
These are false or grossly misleading. The above argument to "simulate real world practice" has no justification. Vitamin C is not a standard treatment for the common cold, even though RCTs have shown that it does differ from placebo.
The authors should have used either an ineffective treatment (vitamin C is not ineffective as shown in our Cochrane review) or the authors should have used some standard treatment for nasal symptoms such as pseudoephedrine or xylometazoline as the comparison.
Although our Cochrane review does show that vitamin C differs from placebo, the dose of vitamin C in de Hei's study is so low that it is unlikely that it has effects. However, if the authors consider that vitamin C dose in their study is so low that it cannot have any effects for the patients, they should not mislead the readers by claiming that they properly compared myAIRVO 2 against vitamin C:
"myAIRVO 2 device was associated with clinically significant reductions in common cold symptoms compared to treatment with vitamin C." (page 22,
"Compared with vitamin C, rhinothermy improves symptoms of the common cold by at least the substantial clinical benefit threshold between days 3 and 5." (page 24, line 47)
These are not based on a valid comparison of their device against vitamin C. There is evidence of dose dependency in the effects of vitamin C up to 6-8 g/day, see http://www.mdpi.com/2072-6643/9/ 4/339 Thus, if a researcher would like to compare some treatment against vitamin C, the proper dose of vitamin C would be 6-8 g/day or even higher and not 0.25 g/day.
It seems to me that the authors may have used vitamin C as a "control" for marketing purposes. Possibly Fisher & Paykel Healthcare Limited might advertice their product with a reference to this study by claiming that myAIRVO 2 device caused "clinically significant reductions in common cold symptoms compared to treatment with vitamin C." Given that many lay people believe in vitamin C, those people might be more interested in the myAIRVO 2 device when it is described as significantly better than vitamin C, compared to adverticing that it is better than no treatment or a genuine placebo.
The reasoning in the manuscript is odd. Thus the authors state that:
"The primary outcome measure was the proportion of recruits who were randomised" (p. 10, line 34) "8.2. Objectives; The objectives of the study: 1. To determine the proportion of potential recruits who would qualify for the feasibility study (provide estimated recruitment time and cost for a randomised controlled trial)." (Protocol) "8.1. Hypothesis This is a feasibility study to assess the process, resources, management and scientific aspects of NHF therapy use in participants with a specific criteria that determines a common cold diagnosis. This will inform a future randomised controlled trial design to ensure methodological robustness." (Protocol)
"finding should be considered with caution, as this was a feasibility study in which efficacy was not the primary outcome measure." (page 3, line 25)
If such arguments were true, why do they use so much space to the comparison of the device against vitamin C in the Results sec tion and claim that their device was demonstrated to be better than vitamin C in the Discussion section.
THE AUTHORS DO NOT FORMULATE WHAT IS THE GOAL OF THEIR TREATMENT
There are several effective treatments for common cold symptoms. NSAIDs can lower fever and decrease pain in throat, pseudoephedrine or xylometazoline are effective for nasal symptoms in many people, cough medicines can make some patients sleep better etc. However, to my knowledge there is no evidence that these treatments make colds shorter. Decrease in the cold symptoms increases the quality of life of the patients.
Another goal in treating colds is to shorten common cold symptoms. In figure 3 they show the KM-curves for the duration of colds with the outcome "time to feeling better" which is a clinically relevant outcome. Why dont the authors calculate the P-value for the difference between the two curves. I extracted the data and calculated logrank test P = 0.4. Thus, there is no evidence that the myAIRVO 2 device makes patients to be cured faster compared with the control. Lack of giving the P-value for the KM curves misleads the reader about the clinical relevance.
Although There are few therapeutic studies on vitamin C, and many of them used low doses and short duration of vitamin C, and they do not justify a conclusion that "vitamin C is ineffective". Absence of evidence is not evidence of absence. https://www.ncbi.nlm.nih.gov/pubmed/23440782 "Outcomes v) Proportion of organisms identified by PCR analysis of nasal swabs taken at baseline;" (page 10, line 43)
Measurements done at baseline cannot be an outcome of a trial.
"Based on this analysis, we propose that a 5 unit change in modified Jackson score is the substantial clinical benefit threshold for this instrument." (page 16, line 53) This is not a reasonable argument. A person may have severe cough disturbing sleep as the only symptom (3 points) and such a patient may consider that there is "substantial clinical benefit" if he or she can start to sleep if the cough decreases to level of 1. That is only 2 point decrease, but many patients would be very glad.
The range of symptom scores is from 7 to 21 (Table 1) . I do not think it is reasonable to consider that the uniform "5 unit" change is relevant for both extremes of the range. We can calculate means for any kind of distributions but all means are not useful. The "5 unit" threshold does not seem helpful for assessing the effects of common cold treatments.
"11.1. Description of the Statistical Design Estimation of the minimally important difference in Jackson score,16 would require a minimum of 25 participants for precision (based on a t statistic). This will be done by evaluating the percentage change in Jackson score on the day the participant first stated they "felt a lot better" compared to baseline." (protocol)
Thus, in the protocol the authors planned to calculate "percentage change in Jackson score" which in my view would be reasonable, but in their manuscript they do not calculate the percentage, but they calculate the unit changes.
"the use of a real-world control treatment increases the external validity of these results" (page 22, line 24) This is false. External validity depends on the selection of participants, on their age, sex distribution, geographic origin, etc. Using vitamin C as a "real-world control treatment" has nothing to do with external validity of the findings.
REVIEWER
Ronald Eccles Emeritus Professor
Cardiff School of Biosciences Cardiff University UK REVIEW RETURNED 11-Oct-2017
GENERAL COMMENTS
An excellent pilot study-I am impressed that this pilot study is being conducted as so few trials are supported by this type of preliminary investigation to sort out issues and perform power calculations. Key challenges will be getting the patients early enough as 48 hours from onset of symptoms is a major problem and how does the patient define onset? Another challenge will be ensuring the patients do use the treatment for two hours-maybe you could give them a timer to record duration of therapy and advise them to try their best for two hours
VERSION 1 -AUTHOR RESPONSE
Editor Comments to Author: -Please complete and include a CONSORT checklist, ensuring that all points are included and state the page numbers where each item can be found. The checklist can be downloaded from here: http://www.consort-statement.org/ Authors reply: Please find our CONSORT checklist uploaded.
-Please make it clear in the title that this is a feasibility study.
Authors reply: We have changed the title as requested to: Randomised controlled trial of rhinothermy for treatment of the common cold: a feasibility study.
-Were data assessors blinded to allocation?
Authors reply: Investigators were blinded to allocation until the point of randomisation but, as described on Page 8, could not be masked to treatment allocation. We have added the following text to page 8 line 172: "Investigators were blinded to allocation until this point. Due to the nature of the interventions and the unequal randomisation design, participants, investigators, and the study statistician could not be masked to treatment allocation."
-Please provide a figure to show what the AIRVO 2 humidifier looks like (it's in the Protocol).
Authors reply: We have provided a figure as requested.
-Reviewer Hemilä comments that the dose of vitamin C is low in the control arm. This needs to be made clear.
Authors reply: Thank you, We have made this clear in the edited version of the manuscript and please find below our detailed response to the reviewer's comments.
Reviewer 1 The main aims of the study were to determine the feasibility of the trial design, exploratory efficacy regarding common cold, a minimum clinically important difference (MCID) for a specific outcome parameter, and the tolerability of the device. The manuscript is well written and illustrative. The medical condition (common cold) is important. The proposed intervention is a novel, interesting approach for treatment. The study designs seem generally sound. The results are well presented. I agree with the authors' conclusions, and I would recommend the publication of the manuscript after revision.
I would be willing to take questions from the authors regarding any of my concerns in order to facilitate the revision process.
1) Page 1, line 5-7 It should be stated in the title of the article that this was a feasibility study.
Page 2, line 10 and page 7, line 8 2) This study was not placebo-controlled. A placebo for this study would be a (preferably) identical looking device (HFNC) without active ingredients. Vitamin C (the control intervention in this study) is not a placebo. Although the effectiveness of Vitamin C is probably rather weak, this was (technically) an active-controlled study. Thus, please refrain from using the term placebo in the manuscript.
Authors reply: Thank you for these comments. We have removed the term "placebo" from the manuscript and refer simply to "controlled" and/or "control" throughout.
3) For the planning of a further trial, randomizing to either rhinothermy + Vitamin C vs. Vitamin C alone could be an option.
Authors reply: Thank you for this suggestion. In our forthcoming study we will use a "sham" version of rhinothermy as a placebo comparator, in line with comment 2 above.
4) Please be consistent with the description of the trial design on page 2, line 10 and page 7, line 8.
Authors reply: Thank you for pointing out that error. We have changed the description on page 7 to match that on page 2.
5) Page 2, line 33-39
Please state only results which are in line with the objectives of the study (page 2, line 6).
Authors reply: The results reported in the abstract and main text are pre-specified outcome measures, as described in the methods section, page 10, Ln 234 to page 11, Ln 243. We have tried to ensure that the main focus of the paper is the primary feasibility outcome but believe it is appropriate to report pre-specified secondary efficacy outcomes whilst acknowledging the limitations and the need for an appropriately powered RCT.
6) Entire manuscript Since this was an exploratory (not a confirmatory) trial, there is no formal level of significance. All pvalues are to be interpreted exploratory. This should be stated in the statistical analysis section. While it is important to present p-values, the term 'significant' should be avoided throughout the entire manuscript.
Authors reply: Thank you for this suggestion. As a feasibility study it is true that this study was not designed to provide the final determination of whether rhinothermy was effective for the treatment of the common cold. However, there was an a-priori hypothesis that rhinothermy may be an effective treatment for the common cold and the efficacy analyses were pre-specified so we would not characterise this as exploratory research. We are conscious of the limitations, including the small sample size, and have presented those within the manuscript.
7) Page 5, line 55 and page 6, line 2-4 It is not entirely clear what is meant by 'sample of the population from which participants would be recruited into an RCT' and 'sample of the population from which participants would be recruited.' Please clarify these 'samples'.
Authors reply: Thank you for pointing this out. We have altered the text to read: "among people with the common cold who are eligible to take part in the study" in both places (page 5 line 126 and page 6 line 128) 8) Page 11, line 25-27 Please state which model(s) included an interaction term.
Authors reply: Thank you for the suggestion. We have now altered the text to c larify that the interaction term was for the mixed linear models looking at difference in Jackson score:
"Mixed linear models with an exponential-in-time covariance matrix were used to estimate the differences in modified Jackson scores by treatment and time. A post hoc interaction term tested if the response in modified Jackson score differed by whether the nasal swab results was positive or not." Page 11 line 259 9) Page 11, line 31-33 Please state for which time points logistic regression was used. Was this a repeated measures regression model?
Authors reply: We have amended the text to clarify that for each participant the time-point used was the day they first felt a lot better. page 11; line 30-35, Logistic regression was used to estimate the Receiver Operating Characteristic curves for the probability of participants first saying they were a lot better compared to the change in baseline modified Jackson score at that particular time.
10) Page 14, Table 1 The Page 15, Table 2 and in the entire manuscript 11) Please be consistent with the terms 'day 1' and 'baseline'. I suppose they refer to the same time point. If yes, please do not use two different terms (the preferable term would be 'baseline' since this clearly indicates a time point BEFORE intervention).
Authors reply: Thank you. We've changed the term "Day 1" to "baseline" as suggested throughout the manuscript.
12) Please be consistent with the number of decimal places shown (day 4).
Authors reply: Thank you for pointing out that error. We have changed it to 1dp.
13) Did the authors analyze the eight domains of the Jackson Score separately? 14) Would these analyses reveal some additional important insights?
Authors reply: We thank the reviewer for this suggestion however we feel that the relatively small data set, the fact that this was not a pre-specified analysis, and the fact that the ordinal nature of each component score would require quite a different analysis to that pre-specified or anticipated at the study design, mean that this analysis would be better carried out in a larger data set as part of a confirmatory RCT.
15) Page 16, Table 3 Please indicate in the table header which outcome is presented in table 3. Again, the preferable term for 'day 1' would be 'baseline'.
Authors reply: Thank you. We've re-arranged the term "Day 1" to "baseline" as suggested and added modified Jackson score to the header of the table.
16) Page 16, section 'Estimation of Minimal Clinically Important Difference (MCID) / Substantial Clinical Benefit (SCB)' Another way to obtain an estimate for the MCID would be to calculate the mean of the change in modified Jackson score from baseline to the first day of reported feeling 'a lot better'.
Authors reply: Thank you for this suggestion. We agree there is more than one approach that can be used to estimate the MCID. We are comfortable with the approach we have used in this study and feel that comparison of different methods is unlikely to be helpful in view of the small sample size. We will consider comparing different techniques for estimating MCID and SCB as part of the full RCT. Another personal preference (and completely optional) is to display 1-S(t) (instead of S(t)), e.g. to mirror the curves, starting at zero. I think it is more intuitively to show the proportion who do feel better.
Authors reply: Thank you for suggestions 18-23, we have amended the figure legend for figure 2 to make it clear what the y-axis denotes, that the error bars represent one SD, and to clarify why day 0 and 1 are not plotted. If the editorial team would like further changes made we would be happy to generate a high-quality version of the graph in the desired format upon acceptance of the manuscript.
Page 19, line 20-24 24) Please present results of the test of interaction (at least a p-value for the test of interaction). 25) Please present these results where the outcomes of the the model including the interaction term is shown (Table 3? ).
Thank you for the suggestion. We now report the interaction term p-value in the text immediately prior to the relevant table:
"There was no evidence of an interaction between the treatment difference in modified Jackson scores for those that were Nasal swab positive or negative (p≥0.17 for all time points)." Page 21 line26) Page 20, Table 6 Please be consistent with the number of decimal places shown.
Thank you for pointing out these errors. We have changed it to 1dp throughout.
Page 24, line 8-18 27) The authors give advice on the sample size of a future trial randomizing into three treatment arms. It is unclear how the overall alpha level is preserved when multiple testing is present and how this affects the total sample size. The authors might want to restrict the advice to a two-armed trial to avoid this problem. 28) In addition, please increase the sample size to 43 subjects per treatment arm to properly account for a 10% drop-out rate.
Authors reply to 27&28: In view of these comments and earlier comments about the merits of using sham rhinothermy we have replaced the sample size calculation with a calculation for a two arm study:
Based on the largest confidence limit for an SD of 6.6 (from the upper CI of the Jackson score at Day 5) a sample size of 76 in each group allows the detection of a difference of 3.5 units, with 90% power and a Type I error rate of 5%. Allowing for a 10% dropout rate, a total of 85 participants would need to be randomised to each group. This would require a total of 170 participants in an RCT investigating two randomised treatments.
29) Further comments (do not need to be addressed in the manuscript) Page 10, line 18
For a feasibility study, an additional qualitative part is often useful. Especially when a novel intervention is used, several aspects such as handling, manageability, difficulties, possible improvements, etc. are difficult to be captured by questionnaire with pre-specified questions and answers. This would be better assessed by semi-structured interviews or focus groups. While this cannot be done for the present study, it might still a useful option for a subsequent trial (e.g. as a substudy).
Authors reply: Thank you for these suggestions. We will consider them as we finalise the design of our RCT.
Reviewer 2 Comments to Author:
MAJOR COMMENTS 1. THE GOAL AND PRIMARY OUTCOME ARE NOT SOUND "8.1. Hypothesis This is a feasibility study to assess the process, resources, management and scientific aspects of NHF therapy use in participants with a specific criteria that determines a common cold diagnosis. This will inform a future randomised controlled trial design to ensure methodological robustness." (Protocol) "9.3. Bias The feasibility study is designed to inform a future randomized controlled trial. Therefore bias is not relevant for the outcomes of this study." (Protocol)
Authors reply: Thank you for your comments. While the primary objective of the feasibility study was to test critical elements of the main RCT design, we believe that it is appropriate and of interest to report the pre-specified outcome measures of this study. We also note the WHO position statement recommending that "The main findings of clinical trials are to be submitted for publication in a peer reviewed journal within 12 months of study completion…". We believe we have an obligation to submit these findings for publication.
We recognise the limitations of our sample size and that the efficacy analyses are secondary analyses and have presented these limitations clearly in the manuscript, page 23 line 96 -page 24 line 109: "Three main limitations apply to these results. Firstly, this study was designed as a feasibility study which means that although the modified Jackson score was an efficacy outcome measure, we did not formally pre-specify it as the primary outcome measure. Secondly, due to the nature of the intervention we were unable to blind participants and investigators to the allocated intervention and a future study aiming to replicate these results should explore the option of sham rhinothermy. Finally, the small sample size means that although this study showed clinically and statistically significant results it can be considered relatively 'fragile', in that the modified Jackson score would only need to change in a small number of participants who received the rhinothermy intervention to match the control group for our conclusions to be different. [34, 35] A formal fragility index cannot be calculated for the change in modified Jackson score as it is not a dichotomous variable. The complete follow-up of all participants helps protect against this fragility, however due to the above limitations a larger replication study is required."
ADMINISTERING VITAMIN C TO THE CONTROL GROUP DOES NOT MAKE SCIENTIFIC SENSE
In the protocol, the authors write: "9.2. Controls. Vitamin C tablets 250mg once per day for 5 days will be used. This will act as the 'control' group and simulate 'real world' practice. A Cochrane review reported that there is no strong evidence to support the use of Vitamin C to improve symptoms in the common cold [15] ." "9.10.1 Interventions b) "Vitamin C tablets" (N=10 participants) This will act as the 'control' group; a Cochrane review reported that there is no strong evidence to support the use of Vitamin C to improve symptoms in the common cold [15] . Subjects randomised to this group will receive a Vitamin C tablet (Healtheries Vit C containing 250mg vitamin C)."
These are false or grossly misleading. The abstract of our Cochrane review (ref 14 of the manuscript and ref 15 of the protocol) states "The severity of colds was also reduced by regular vitamin C administration" and the numerical data are shown in the main text and forest plots. https://www.ncbi.nlm.nih.gov/pubmed/23440782
The above argument to "simulate real world practice" has no just ification. Vitamin C is not a standard treatment for the common cold, even though RCTs have shown that it does differ from placebo.
Authors reply: Thank you for raising these very interesting points.
To ensure our statement on Vitamin C in the introduction of the manuscript (pg 4, line 43) is in accordance with your Cochrane review summary and we have adjusted the wording as follows: Page 4 line 91 "Regular supplementation with vitamin C has a small effect on cold duration, but therapeutic supplementation once symptoms develop lacks evidence of efficacy. [14] It is unlikely that supplementation with low-dose vitamin C once symptomatic will reduce symptom severity or duration."
We agree the statements in the protocol should have been more specific to acknowledge the current lack of evidence for vitamin C as an acute therapy rather than a blanket statement about overall efficacy. The manuscript does not contain these errors
We acknowledge there is no standard treatment for the common cold but felt it was appropriate to have a comparator treatment to try and mitigate against getting an efficacy signal from rhinothermy purely because of the placebo effect. Vitamin C is commonly used as a common cold remedy and is available over the counter in the doses used in our study so we believe this is a reasonable real -world comparator. The intention of the study was not to test the efficacy of vitamin C and we intended lowdose vitamin C to act as a placebo control as we consider it very unlikely that supplementation with vitamin C once a person with the common cold is symptomatic has therapeutic efficacy. In light of the comments of reviewer 1 we have changed the term from placebo-control to control throughout the manuscript and now emphasise throughout the manuscript that we used low-dose vitamin C In order to be clear that we did not attempt to compare rhinothermy against regular vitamin C supplementation, we have said in the manuscript (page 9, line 215) "Low-dose Vitamin C was used as a control. As therapeutic use of Vitamin C after symptoms develop has not been shown to consistently reduce the duration of colds or improve cold symptoms, participants were not expected to derive benefit above that obtained by the placebo effect. The low dose of vitamin C used in this study is freely available in pharmacies in New Zealand but is unlikely to be of benefit when taken after symptoms develop, as opposed to regular supplementation."
"myAIRVO 2 device was associated with clinically significant reductions in common cold symptoms compared to treatment with vitamin C." (page 22, line 14)
Authors reply: As explained above, our intent was to choose a control which is frequently used in the community but we felt unlikely to provide benefit beyond a placebo effect. That is why low-dose vitamin C was used. In addition to the amendment above we now refer to the control arm as low-dose vitamin C throughout the paper to ensure that it is clear we are not making a claim related to other doses of vitamin C.
"The primary outcome measure was the proportion of recruits who were randomised" (p. 10, line 34) "8.2. Objectives; The objectives of the study: 1. To determine the proportion of potential recruits who would qualify for the feasibility study (provide estimated recruitment time and cost for a randomised controlled trial)." (Protocol) "8.1. Hypothesis This is a feasibility study to assess the process, resources, management and scientific aspects of NHF therapy use in participants with a specific criteria that determines a common cold diagnosis. This will inform a future randomised controlled trial design to ensure methodological robustness."
If such arguments were true, why do they use so much space to the comparison of the device against vitamin C in the Results section and claim that their device was demonstrated to be better than vitamin C in the Discussion section.
Authors reply: Thank-you for allowing us to clarify the purpose of our publication, which hopefully we have done in response to your first comment. We have tried to ensure that the main focus of the paper is the primary feasibility outcome but believe it is appropriate to report pre-specified secondary efficacy outcomes whilst acknowledging the limitations and the need for an appropriately powered RCT.
THE AUTHORS DO NOT FORMULATE WHAT IS THE GOAL OF THEIR TREATMENT
There are several effective treatments for common cold symptoms. NSAIDs can lower fever and decrease pain in throat, pseudoephedrine or xylometazoline are effec tive for nasal symptoms in many people, cough medicines can make some patients sleep better etc. However, to my knowledge there is no evidence that these treatments make colds shorter. Decrease in the cold symptoms increases the quality of life of the patients.
Another goal in treating colds is to shorten common cold symptoms. Our Cochrane review (ref 14 in the manuscript) shows that vitamin C can shorten the duration of colds and my meta-analysis on zinc lozenges (ref 13 in the manuscript) shows that zinc lozenges can shorten the duration of colds.
Thus, de Hui et al. do not formulate whether their primary goal is to alleviate symptoms or to shorten the duration of colds.
Authors reply: As a feasibility study, efficacy was not the primary outcome of this study. Both symptom severity and symptom duration were pre-specified secondary outcome measures for this study and we are interested in the potential effects of rhinothermy on each. For the full RCT which will have efficacy as the primary objective we agree we will have to prioritise one over the other but at this stage both were secondary outcome measures.
Thank you for highlighting references 13 and 14. As per the comments above, we have clarified our wording in regards to vitamin C. We have also removed the comments regarding zinc as they are not required.
In figure 3 they show the KM-curves for the duration of colds with the outcome "time to feeling better" which is a clinically relevant outcome. Why dont the authors calculate the P-value for the difference between the two curves. I extracted the data and calculated logrank test P = 0.4. Thus, there is no evidence that the myAIRVO 2 device makes patients to be cured faster compared with the control. Lack of giving the P -value for the KM curves misleads the reader about the clinical relevance.
Authors reply: We agree it is appropriate to specify the p-value and in the original manuscript it is in the text on pg 17: "The hazard ratio (95% CI) for feeling 'a lot better' rhinothermy compared to c ontrol was 1.33 (0.60 to 2.98), p=0.48, which favoured the rhinothermy group." It is clearly stated in the text that efficacy was not the primary outcome variable and the small sample size means that we were not powered to draw firm conclusions on efficacy outcome measures.
Although Table 3 and Figure 2 indicate that symptoms were less in the myAIRVO 2 device participants, it is not obvious what conclusions should be drawn.
Authors reply: In the first paragraph of the discussion, page 23 line 409, we suggest that the answer to that is: "Although not a primary outcome for the study, in participants with established common cold symptoms, rhinothermy with the modified myAIRVO 2 device was associated with clinically important reductions in common cold symptoms compared to treatment with low-dose vitamin C."
We then state the major limitations which mean that a further study is required, lines 419 to 430: "Three main limitations apply to these results. Firstly, this study was designed as a feasibility study which means that although the modified Jackson score was a pre-specified efficacy outcome measure, we did not formally specify it as the primary outcome measure. Secondly, due to the nature of the intervention we were unable to blind participants and investigators to the allocated intervention and a future study aiming to replicate these results should explore the option of sham rhinothermy. Finally, the small sample size means that although this study showed clinically and statistically significant results it can be considered relatively 'fragile', in that the modified Jackson score would only need to change in a small number of participants who received the rhinothermy intervention to match the control group for our conclusions to be different. [34, 35] A formal fragility index cannot be calculated for the change in modified Jackson score as it is not a dichotomous variable. The complete follow-up of all participants helps protect against this fragility, however due to the above limitations a larger replication study is required."
First, the authors pool all symptoms to a single symptom score and they do not show the comparisons of separate symptoms. Given that the device influences the nasal region, it is possible that the major (or all?) effects are limited to the nasals symptoms.
Second, there are widely used treatments for the nasal symptoms such as pseudoephedrine and xylometazoline and it would be relevant to compare the device eg against one or both of them, instead of comparing just to an ineffective treatment. A three arm trial would be useful to include the device and no treatment and eg pseudoephedrine.
Authors reply: Thank you for this suggestion which we will consider as we finalise the design of the full RCT.
MINOR COMMENTS "Zinc lozenges in high doses may reduce cold duration but not symptom severity. This is false, reference 13 was focused on the duration of colds. It did not carry out any analyses on cold severity. Thus, reference 13 does not give any basis for the above sentence. Many zinc lozenge trials have reported that symptom severity was reduced.
Authors reply: Thank you for pointing out this error and we have removed this statement.
"Regular supplementation with vitamin C has a small effect on cold durat ion but therapeutic supplementation once symptoms develop is ineffective.
[14] (page 4, line 45) BMJ has published two papers with an identical title: Absence of evidence is not evidence of absence https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2550545/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC351831/ There are few therapeutic studies on vitamin C, and many of them used low doses and short duration of vitamin C, and they do not justify a conclusion that "vitamin C is ineffective". Absence of evidence is not evidence of absence. https://www.ncbi.nlm.nih.gov/pubmed/23440782
Authors reply: We agree that absence of evidence is not evidence of absence and to avoid misunderstanding have amended our comments on the efficacy of vitamin C as laid out in our previous responses.
"Outcomes v) Proportion of organisms identified by PCR analysis of nasal swabs taken at baseline;" (page 10, line 43)
Authors reply: We agree that efficacy outcomes cannot be taken from baseline data. However, in the context of a feasibility study measurements performed at baseline can be very informative with regards to process related outcomes and can therefore be specified as outcome measures. For example our primary outcome was the proportion of recruits who were randomised and this information is available from the baseline data.
"Based on this analysis, we propose that a 5 unit change in modified Jackson score is the substantial clinical benefit threshold for this instrument. The range of symptom scores is from 7 to 21 (Table 1) . I do not think it is reasonable to consider that the uniform "5 unit" change is relevant for both extremes of the range. We can calculate means for any kind of distributions but all means are not useful. The "5 unit" threshold does not seem helpful for assessing the effects of common cold treatments.
"11.1. Description of the Statistical Design Estimation of the minimally im portant difference in Jackson score,16 would require a minimum of 25 participants for precision (based on a t statistic). This will be done by evaluating the percentage change in Jackson score on the day the participant first stated they "felt a lot better" compared to baseline." (protocol)
Authors reply: The reviewer raises an important point that in part will be related to ceiling and floor effects, but we should point out that for those with low scores a percentage change would be quite a lot smaller than a percentage change at higher doses. The meaning of variance estimates for variables scaled as percentages is also quite unclear. Percentages are only scaled from zero 100 so it is highly unlikely that normal distribution assumptions would lead to a straight -forward analysis plan. Finally it is generally accepted that changes on the units of measurement are far preferred to percentage change from baseline for continuous variables. We think the floor and ceiling effects and related issues about the clinical meaning of absolute c hanges across the range of scores would be better addressed in a larger dataset now that we have established that an absolute change of 5 units appear to be a reasonable estimate of the MCID.
"the use of a real-world control treatment increases the external validity of these results" (page 22, line 24) This is false. External validity depends on the selection of participants, on their age, sex distribution, geographic origin, etc. Using vitamin C as a "real-world control treatment" has nothing to do with external validity of the findings. Entire manuscript In their response the authors state that 'there was an a-priori hypothesis that rhinothermy may be an effective treatment for the common cold and the efficacy analyses were pre-specified so we would not characterise this as exploratory research.'. Even with pre-specified hypotheses, this trial is not a confirmatory efficacy trial. The trials objective is not about confirmatory efficacy, and there is no pre-specified single primary efficacy outcome (for a single time point). In addition, multiplicity (multiple testing) is present. Hence, all results of this trial are considered exploratory. As a consequence, there is no formal level of significance. All p-values are to be interpreted exploratory. This must be stated in the statistical analysis section. In addition, the term 'significant' must be avoided throughout the entire manuscript.
VERSION 2 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author:
Reviewer: 3
Reviewer Name: Ronald Eccles 
Abstract
Please state only results which are in line with the objectives of the study and the outcomes presented in the abstract. Following the BMJ Open Author Guideance: 'primary and secondary outcome measures should be given'.
Thank you for this suggestion. We have amended the abstract in line with you suggestion and added the secondary outcomes. That section of the abstract now reads:
Primary and secondary outcome measures: The primary outcome was the proportion of screened candidates who were randomised. Secondary outcomes included: Proportion of randomised participants who completed the study; modified Jackson scores from randomisation to 10 days after initiation of randomised regimen; time until feeling "a lot better" compared to study entry; time until resolution of symptoms or symptom score at 10 days post randomisation; proportion of organisms identified by PCR analysis of nasal swabs taken at baseline; the patterns of use of the rhinothermy device; estimated adherence of the control group; and rhinothermy device tolerability. Hopefully the figures are viewable on the manuscript we have now uploaded. We have amended the figure and labelling in line with the suggestions and inc luded baseline values. For a number of reasons we would respectfully suggest that presenting the SD in the figure is the appropriate approach. Firstly, the 95% CI is always narrower than the error bars set at plus or minus one standard deviation and so could give an air of spurious precision. Secondly, we had presented the SD error bars because in the text as it stands we don't present summary data descriptions for the change from baseline so an interested reader could get these from the plot. Finally, it was a randomised trial so the interest is not individual study arms 95% CI for means but a confidence interval for a comparison of randomised arms (which we have presented in Table 3 ). To ensure all data the reader may wish to have are presented, we have added an additional table (S1) as supplementary material. This provides the mean (SD) and 95% CI of the mean change from baseline for both rhinothermy and control groups.
Entire manuscript
In their response the authors state that 'there was an a-priori hypothesis that rhinothermy may be an effective treatment for the common cold and the efficacy analyses were pre-specified so we would not characterise this as exploratory research.'.
Even with pre-specified hypotheses, this trial is not a confirmatory efficacy trial. The trials objective is not about confirmatory efficacy, and there is no pre-specified single primary efficacy outcome (for a single time point). In addition, multiplicity (multiple testing) is present. Hence, all results of this trial are considered exploratory. As a consequence, there is no formal level of significance. All p-values are to be interpreted exploratory. This must be stated in the statistical analysis section. In addition, the term 'significant' must be avoided throughout the entire manuscript.
We are happy to accept this suggestion and have changed the manuscript accordingly. Thank you for your suggestions.
VERSION 3 -REVIEW
REVIEWER
Stephanie Roll Charité -Universitätsmedizin Berlin Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie Germany REVIEW RETURNED 27-Feb-2018
GENERAL COMMENTS
The authors have further revised and improved the manuscript and I would suggest the publication of the current version.
